A role for intravenous lidocaine in severe cancer-related neuropathic pain at the end-of-life.
BACKGROUND
Systemic administration of lidocaine has been widely reported to provide effective analgesia in both cancer and non-malignant pain.


METHODS
We report the use of intravenous lidocaine in the management of cancer-related neuropathic pain and its pivotal role in restoring function and facilitating end-of-life care at home.
Buchanan
D Deans
DD
Ninewells Hospital and Medical School, Dundee, UK. deansbuchanan@nhs.net
J MacIvor
Frances
F
D000368:Aged; D000779:Anesthetics, Local / Q000008:administration & dosage; D001416:Back Pain / Q000188:drug therapy* / Q000209:etiology; D001859:Bone Neoplasms / Q000556:secondary*; D006801:Humans; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000150:complications*; D008012:Lidocaine / Q000008:administration & dosage*; D008297:Male; D051346:Mobility Limitation; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D010166:Palliative Care / Q000379:methods; D011843:Radiculopathy / Q000150:complications*; D013727:Terminal Care / Q000379:methods*
D000779:Anesthetics, Local; D008012:Lidocaine